Skip to main navigation Skip to search Skip to main content

Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy

  • Matthew Cates*
  • , Matthew Donati
  • , Sophie Gillet
  • , Andrew Ustianowski
  • , James Galloway
  • *Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

15 Citations (Scopus)

Abstract

Chickenpox and shingles can be more severe and occasionally life threatening in immunosuppressed patients. As such, some groups warrant a more detailed history, serological testing and consideration of prophylaxis following contact with the virus. Active disease may also require more aggressive treatment with antivirals. Guidance for the use of varicella zoster immunoglobulin has recently been updated by Public Health England with important implications for rheumatology patients.

Original languageEnglish
Pages (from-to)596-605
Number of pages10
JournalRheumatology
Volume57
Issue number4
DOIs
Publication statusPublished - 1 Apr 2018

Bibliographical note

Publisher Copyright:
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Acyclovir
  • Antiviral
  • Chickenpox
  • Contact
  • Immunosuppressed
  • Infection
  • Shingles
  • VZIG
  • VZV
  • Vaccine
  • Varicella
  • Varicella zoster immunoglobulin
  • Varicella zoster virus
  • Zoster

Fingerprint

Dive into the research topics of 'Managing varicella zoster virus contact and infection in patients on anti-rheumatic therapy'. Together they form a unique fingerprint.

Cite this